Source: Breathe, 17 (4) 210113; 10.1183/20734735.0113-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Gokul Erumbala, Sabu Anzar, Amjad Tonbari, Ramadan Salem, Colin Powell. Stating the obvious: intravenous magnesium sulphate should be the first parenteral bronchodilator in paediatric asthma exacerbations unresponsive to first-line therapy. Breathe, 17 (4) 210113; 10.1183/20734735.0113-2021

Member's Comments

No comment yet.

Related content which might interest you: Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 The use of intravenous aminophylline in treatment of exacerbations of COPD Source: Annual Congress 2004 - Acute exacerbations and drug therapy in COPD Year: 2004 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma Source: Annual Congress 2007 - New drugs for asthma Year: 2007 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002 Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Inhaled corticosteroid therapy on admission of hospitalized patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020 Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010 Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004